International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction-Reference-Cited by-同舟云学术

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Published:2024-09-08 Issue: Volume: Page:1-11
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Yun Sergi¹²³⁴,Palladini Giovanni⁵⁶,Anderson Lisa J.⁷,Cariou Eve⁸,Wang Ronnie⁹,Angeli Franca S.¹⁰,Ebede Ben¹⁰,Garcia-Pavia Pablo¹¹¹²¹³¹⁴

Affiliation:

1. Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain

2. Community Heart Failure Program, Cardiology and Internal Medicine Department, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain

3. Internal Medicine Department, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain

4. Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Carlos III Health Institute (ISCIII), Madrid, Spain

5. Department of Molecular Medicine, University of Pavia, Pavia, Italy

6. Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy

7. St George’s University of London, London, UK

8. Department of Cardiology, Rangueil University Hospital, Toulouse, France

9. Pfizer Inc, Groton, CT, USA

10. Pfizer Inc, New York, NY, USA

11. Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

12. Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Madrid, Spain

13. Universidad Francisco de Vitoria, Madrid, Spain

14. Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Madrid, Spain

Funder

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2024.2398446

Reference36 articles.

1. Transthyretin Amyloid Cardiomyopathy

2. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System

3. A new staging system for cardiac transthyretin amyloidosis

4. Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction

5. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy